Treatment Strategy in Patients with Unresectable Stage I-III

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Related Keywords

, Recent Updates , Translating Evidence , Clinical Practice , Unresectable Stage , Nsclc , Early Nsclc , Non Small Cell Lung Cancer , Asco 2023 , Localized Disease , Presection , Surgery , Staging , Chemoimmunotherapy , Immunotherapy , Ohio , Molecular Testing , Liquid Biopsy , Tissue Biopsy , Ngs Testing , Egfr , Talk ,